FDA Adverse Event Injury Summary report: N

MITROFLOW LXA

MDR report key: 7608456 · Received June 16, 2018

Report

Report Number
3004478276-2018-00217
Event Type
Injury
Date Received
June 16, 2018
Date of Event
May 7, 2018
Report Date
October 12, 2018
Manufacturer
LIVANOVA CANADA CORP.
Product Code
LWR
PMA / PMN Number
P060038
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
IN, US
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 0

THE MANUFACTURING AND MATERIAL RECORDS FOR THE MITROFLOW BIOPROSTHETIC PERICARDIAL HEART VALVE, MODEL # LXA21, S/N # (B)(4), AS THEY PERTAIN TO THE REPORTED EVENT, WERE RETRIEVED AND REVIEWED BY QUALITY ENGINEERING AT LIVANOVA CANADA CORP. THE RESULTS CONFIRMED THAT THIS VALVE SATISFIED ALL MATERIAL, VISUAL, AND PERFORMANCE STANDARDS REQUIRED FOR A LXA21 MITROFLOW AORTIC PERICARDIAL HEART VALVE AT THE TIME OF MANUFACTURE AND RELEASE.

Additional Manufacturer Narrative · 0

UPON REVIEW OF THE RECEIVED INFORMATION REGARDING THE CASE THE MANUFACTURER HAS IDENTIFIED THAT NO FURTHER INVESTIGATIONS ARE POSSIBLE BASED ON THE LIMITED INFORMATION. THE DEVICE LOCATION IS PRESENTLY UNKNOWN AND THUS THE DEVICE CANNOT BE RETURNED FOR ANALYSIS. IN ADDITION THE SITE HAS COMMENTED THAT NO FURTHER INFORMATION IS AVAILABLE. THE DHR REVIEW CONFIRMED THE DEVICE MET ALL REQUIRED STANDARDS AT THE TIME OF MANUFACTURER AND RELEASE, HOWEVER BASED ON THE LIMITED INFORMATION THE ROOT CAUSE OF THE EVENT CANNOT BE ESTABLISHED AT THIS TIME. IF FURTHER INFORMATION IS RECEIVED REGARDING THE ADVERSE EVENT THE MANUFACTURER WILL REASSESS THE INVESTIGATION. FIELDS CHANGED.

Additional Manufacturer Narrative · 1

DEVICE DISPOSITION PRESENTLY UNKNOWN.

Description of Event or Problem · 1

ON (B)(6) 2014 A MITROFLOW LXA21 BIOLOGICAL HEART VALVE PROSTHESIS WAS IMPLANTED. ON (B)(6) 2018 THE VALVE WAS EXPLANTED AND A PERCEVAL PVS23 WAS IMPLANTED AS A REPLACEMENT. NO FURTHER INFORMATION RECEIVED.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
450617 MITROFLOW LXA TISSUE HEART VALVE LWR LIVANOVA CANADA CORP. LXA21

Patients

Seq Age Sex Outcome Treatment
1 72 YR Required Intervention